Amgen and Merck will
collaborate to evaluate the safety
and efficacy of a drug combination
to treat patients with mid to late
stage melanoma.
The companies said they had
entered an agreement through a
subsidiary to investigate talimogene
laherparepvec, an investigational
oncolytic immunotherapy
combined with MK-3475,
an investigational anti-PD-1
immunotherapy, in a phase 1b/2
study.
The open-label clinical trial would
be conducted in two parts in
autumn.The above article was sent to subscribers in Pharmacy Daily's issue from 10 Feb 14 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 10 Feb 14
THE role and significance of community pharmacy in regional areas was a key focus of discussion for the Nationals leader David Littleproud during last week’s visit to Orana Mall Pharmacy as part of a regional tour.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.